The Centers for Medicare & Medicaid Services (CMS) reversed a payment coding decision that would have greatly enticed physicians to prescribe a very expensive medication, ranibizumab (Lucentis), to treat wet macular degeneration instead of a far more affordable drug, bevacizumab (Avastin), a development praised by Sen Herb Kohl (D, Wis), chairman of the Senate Special Committee on Aging. Both drugs are manufactured by Genentech Inc.
“I’m pleased that CMS heeded the concerns of the medical eye care community and the Aging Committee,” said Kohl in an October 28 statement.
Mitka M. Eye Drug Reversal. JAMA. 2009;302(22):2423. doi:10.1001/jama.2009.1804
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: